| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_875d205f61352cd8f69d87c338056020 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2004-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_453e1ad684596c5feaf5692918514276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2323f6e1884a3fe846e3f2d92ee5f6ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8e5a7f714e6972453c00374ff7e761f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0e6c7acf6a2ac81ae5d22fac23587de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55bad8e8aebe49ff90d16d1f5cded51f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b27ba59e8c645d40a0f6f10828a64867 |
| publicationDate |
2005-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20050077173-A |
| titleOfInvention |
Indirubin derivatives having anticancer property against human cancer cell line |
| abstract |
The present invention relates to an indirubin derivative having anticancer activity in human cancer cell lines and apoptosis effect through induction of differentiation in leukemia cell lines. More specifically, by synthesizing a derivative of indirubin known as a CDK (Cyclin-dependent kinase) inhibitor, and selectively measuring leukemia cell lines and various cancer cells by measuring growth inhibitory activity of human cancer cell lines and apoptosis effect through differentiation of leukemia cell lines. The company has developed a new indirubin compound with excellent cancer cell inhibition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020517743-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018194309-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459311-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114920728-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11370779-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019088677-A1 |
| priorityDate |
2004-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |